A cloned frog vasoactive intestinal polypeptide pituitary adenylate cyclase-activating polypeptide receptor exhibits pharmacological and tissue distribution characteristics of both VPAC1 and VPAC2 receptors in mammals

被引:41
|
作者
Alexandre, D
Anouar, Y
Jegou, S
Fournier, A
Vaudry, H [1 ]
机构
[1] Univ Rouen, European Inst Peptide Res IFRMP 23, Lab Cellular & Mol Neuroendocrinol, CNRS,INSERM,U413, F-76821 Mont St Aignan, France
[2] Univ Quebec, Inst Natl Rech Sci Sante, Pointe Claire, PQ H9R 1G6, Canada
关键词
D O I
10.1210/en.140.3.1285
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Three receptor subtypes for the neuropeptides vasoactive intestinal peptide (VIP) and pituitary adenylate cyclase-activating polypeptide (PACAP) have been identified in mammals: the PAC(1) receptor (PAC(1)-R) which is selectively activated by PACAP, and two VPAC receptors (VPAC(1)-R and VPAC(2)-R), which are equally stimulated by PACAP and VIP. The structures of PACAP and VIP have been well conserved during evolution, but little is known about VIP/PACAP receptors in nonmammalian species. An amphibian VTP/PACAP receptor complementary DNA (cDNA) has been cloned and characterized from a frog (Rana ridibunda) pituitary cDNA library. The predicted protein contains seven putative transmembrane domains and exhibits the highest sequence identity (65%) with the human VPAC(1)-R. The cloned cDNA was transiently expressed in LLC-PK1 cells, and its pharmacological profile was determined in comparison with the human VPAC(1)-R. Both PACAP and VIP stimulated cAMP accumulation through the cloned receptor with an EC50 of about 30 nM. In contrast, secretin, at concentrations that stimulate the human VPAC(1)-R, had no effect on cAMP production. RT-PCR analysis revealed the widespread distribution of this frog VIP/PACAP receptor in peripheral tissues. In situ hybridization histochemistry using a complementary RNA probe showed that the receptor gene is highly expressed in several hypothalamic and thalamic nuclei and to a lesser extent, in the pallium and striatum. In the pituitary, the highest messenger RNA levels were detected in the distal lobe. Taken together, these data show that the cloned frog receptor shares several common features with both the VPAC(1)-R and VPAC(2)-R of mammals; the frog receptor exhibits the highest sequence identity with mammalian VPAC(1)-R, but the lack of effect of secretin and the brain distribution of the receptor are reminiscent of the characteristics of the mammalian VPAC(2)-R. The sequence of the frog receptor should thus prove useful to decipher the structure-activity relationships of the VIP/PACAP receptor family.
引用
收藏
页码:1285 / 1293
页数:9
相关论文
共 50 条
  • [11] RECEPTORS FOR PITUITARY ADENYLATE CYCLASE-ACTIVATING POLYPEPTIDE - COMPARISON WITH VASOACTIVE-INTESTINAL-PEPTIDE RECEPTORS
    ARIMURA, A
    TRENDS IN ENDOCRINOLOGY AND METABOLISM, 1992, 3 (08): : 288 - 294
  • [12] EFFECT OF PITUITARY ADENYLATE-CYCLASE ACTIVATING POLYPEPTIDE AND ITS ANALOGUES ON THE SPECIFIC PAC1 AND VPAC1/VPAC2 RECEPTORS ON THE CELL BODIES OF PRIMARY SENSORY NEURONS AND TRANSFECTED CELL LINES
    Szoke, E.
    Saghy, E.
    Payrits, M.
    Reglodi, D.
    Toth, G.
    Couvineau, A.
    Helyes, Z.
    BASIC & CLINICAL PHARMACOLOGY & TOXICOLOGY, 2014, 115 : 114 - 114
  • [13] Pituitary adenylate cyclase-activating polypeptide (PACAP) and PACAP/vasoactive intestinal polypeptide receptors: Actions on the anterior pituitary gland
    Rawlings, SR
    Hezareh, M
    ENDOCRINE REVIEWS, 1996, 17 (01) : 4 - 29
  • [14] PITUITARY ADENYLATE-CYCLASE ACTIVATING POLYPEPTIDE AND ITS ANALOGUES ACTIVATE THE SPECIFIC PAC1 AND VPAC1/VPAC2 RECEPTORS ON THE CELL BODIES OF PRIMARY SENSORY NEURONS AND TRANSFECTED CELL LINES
    Saghy, E.
    Szoke, E.
    Banki, E.
    Reglodi, D.
    Toth, G.
    Couvineau, A.
    Helyes, Zs
    JOURNAL OF MOLECULAR NEUROSCIENCE, 2013, 51 : S204 - S205
  • [15] Generation of highly selective VPAC2 receptor agonists by high throughput mutagenesis of vasoactive intestinal peptide and pituitary adenylate cyclase-activating peptide
    Yung, SL
    Dela Cruz, F
    Hamren, S
    Zhu, J
    Tsutsumi, M
    Bloom, JW
    Caudle, M
    Roczniak, S
    Todd, T
    Lemoine, L
    MacDougall, M
    Shanafelt, AB
    Pan, CQ
    JOURNAL OF BIOLOGICAL CHEMISTRY, 2003, 278 (12) : 10273 - 10281
  • [16] Properties of the pituitary adenylate cyclase-activating polypeptide I and II receptors, vasoactive intestinal peptide(1), and chimeric amino-terminal pituitary adenylate cyclase-activating polypeptide vasoactive intestinal peptide(1) receptors: Evidence for multiple receptor states
    VanRampelbergh, J
    Gourlet, P
    DeNeef, P
    Robberecht, P
    Waelbroeck, M
    MOLECULAR PHARMACOLOGY, 1996, 50 (06) : 1596 - 1604
  • [17] Reduced immunoreactivities of a vasoactive intestinal peptide and pituitary adenylate cyclase-activating polypeptide receptor (VPAC, receptor) in the cerebral cortex, hippocampal region, and amygdala of aged rats
    Joo, KM
    Chung, YH
    Lim, HC
    Lee, KH
    Cha, CI
    BRAIN RESEARCH, 2005, 1064 (1-2) : 166 - 172
  • [18] Heterogeneity of pituitary adenylate cyclase-activating polypeptide and vasoactive intestinal polypeptide receptors in rat intrinsic cardiac neurons
    DeHaven, WI
    Cuevas, J
    NEUROSCIENCE LETTERS, 2002, 328 (01) : 45 - 49
  • [19] Pituitary adenylate cyclase-activating polypeptide, vasoactive intestinal polypeptide and their receptors:: distribution and involvement in the secretion of Podarcis sicula adrenal gland
    Valiante, Salvatore
    Prisco, Marina
    Sciarrillol, Rosaria
    De Falco, Maria
    Capaldo, Anna
    Gay, Flarninia
    Andreuccetti, Piero
    Laforgia, Vincenza
    Varano, Lorenzo
    JOURNAL OF ENDOCRINOLOGY, 2008, 196 (02) : 291 - 303
  • [20] Mechanisms of phospholipase C activation by the vasoactive intestinal polypeptide/pituitary adenylate cyclase-activating polypeptide type 2 receptor
    MacKenzie, CJ
    Lutz, EM
    Johnson, MS
    Robertson, DN
    Holland, PJ
    Mitchell, R
    ENDOCRINOLOGY, 2001, 142 (03) : 1209 - 1217